Status:
COMPLETED
Evaluation of the Effect of Body Weight and Composition on Iron Absorption and Blood Volume
Lead Sponsor:
Swiss Federal Institute of Technology
Collaborating Sponsors:
Wageningen University
Universidad de Monterrey
Conditions:
Obesity
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
A total of 75 subjects will be recruited for this study (25 normal weight, 25 overweight, 25 obese). In each subject blood volume will be determined using the minimally invasive carbon monoxide-rebrea...
Detailed Description
Obesity has repeatedly been shown to be a risk factor for iron deficiency. The reason for this is believed to be reduced iron absorption as a result of increased circulating hepcidin concentrations. H...
Eligibility Criteria
Inclusion
- Women
- Age 18-45 years
- Pre-menopausal (no absence of a menstrual cycle in the past 12 months)
- BMI 18.5-39.9 kg/m2 (n=25 18.5-24.9, n=25 25-29.9, n=25 30-39.9)
- Apparently healthy (no significant medical conditions that could influence iron or inflammatory status other than obesity (i.e., cancer, HIV/AIDS, inflammatory bowel disease, gastrointestinal bleeding, and rheumatoid arthritis, renal disease or hemochromatosis) (judged by study physician)
Exclusion
- Moderate/sever anemia (Hb\<11 g/dl)
- Use of medication which interferes with study measurements (judged by the study physician)
- Smoking
- Pregnancy and lactation; planning to become pregnant during the course of the study (pregnancy test will be conducted at visit 2 and subjects will be asked about contraception\*)
- Consumption of vitamin- or mineral supplements unless they consent to discontinue intake two weeks before the start of the study until the final blood sampling
- Prior participation in studies using stable iron isotopes
- Food allergies/intolerances (gluten, lactose, milk protein)
- Blood donation during the two months prior to the study
- Major injuries during the 6 months prior to the study
- Illness during the 4 weeks prior to the study (judged by study physician)
- Administration of recombinant erythropoietin (rhEPO)
- More than 5 days at altitudes above 1600 m above sea level during the 3 weeks prior to the study
- Long distance flight (\>8 h) during the 3 weeks prior to the study
- Chronic alcohol abuse
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT01884506
Start Date
June 1 2013
End Date
October 1 2013
Last Update
October 14 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Human Nutrition Laboratory, ETH Zurich
Zurich, Switzerland, 8092